LONDON, June 9 (Reuters) - GSK (GSK.L) has agreed to ​buy U.S.-listed cancer drug developer Nuvalent (NUVL.O) for $10.6 billion in its largest deal in more than a decade, marking a strategic shift und...

Britain's blue-chip FTSE 100 hit its lowest since mid-May on Tuesday, bogged down by losses in heavyweight ​lenders HSBC and Standard Chartered, while energy giants also lost ‌ground amid declining oi...

GSK is paying $124 a share in cash for Nuvalent, a 40% premium to Monday's closing price of $88.49 for the Cambridge, Mass., company.